Eckert & Ziegler to Build cGMP Facility for Radiopharmaceutical Services in USA

Eckert & Ziegler is proud to announce that it is expanding its production site in Wilmington just north of Boston, Massachusetts of a new production facility for the contract manufacturing of radiopharmaceuticals. This new cGMP clean room suite will be a 21 CFR 211 compliant, radiopharmaceutical manufacturing facility dedicated to late stage investigational and commercial stage radiopharmaceuticals. Together with our current facilities in Germany, the new U.S. based cGMP facility, will enable Eckert & Ziegler to provide radiopharmaceutical development services to companies looking for US and worldwide contract manufacturing.

“To meet the growing global demand for radiopharmaceutical services involving both imaging and therapy products, we have decided to make this investment. At the moment, a large number of radiopharmaceutical substances from international pharmaceutical companies are in advanced clinical trials, some of them for broad indications such as prostate cancer," explains Dr. Lutz Helmke, member of the Executive Board of Eckert & Ziegler AG and responsible for the Medical segment. "With the new cGMP facility, we offer both regional and global pharmaceutical companies a one-stop service for a variety of radio-pharmaceutical services under cGMP conditions."


Currently, a production facility is being completed at the Wilmington, MA site to manufacture yttrium-90 based radiopharmaceuticals for the treatment of liver cancer. In the future, the company will expand its European production capacity for Lutetium-177 labeled drugs to its U.S. site.

Lutetium-177 is a coveted active ingredient in many new cancer therapy drugs. "Due to the large number of studies in which lutetium-177 is being clinically tested worldwide, we expect an increasing demand for this isotope and related services in the coming years. With our production sites in Europe, Asia and North America, we believe we are ideally positioned to meet this demand," adds Dr. Lutz Helmke.

The new cGMP suite, will enable Eckert & Ziegler to offer complete early development services, including process development and scale-up, CMC manufacturing and packaging, product release and stability programs. The company will thus be able to manufacture products on a clinical scale of phases I, II and III and for commercial use as a radiopharmaceutical contract manufacturer.

Über die Eckert & Ziegler Strahlen- und Medizintechnik AG

Eckert & Ziegler Strahlen- und Medizintechnik AG with more than 800 employees, is one of the world’s largest providers of isotope-related components for nuclear medicine and radiation therapy. The company offers services for radiopharmaceuticals at various locations, from early development to commercialization. Eckert & Ziegler shares (ISIN DE0005659700) are listed in the TecDAX index of Deutsche Börse.
Contributing to saving lives.

Firmenkontakt und Herausgeber der Meldung:

Eckert & Ziegler Strahlen- und Medizintechnik AG
Robert-Rössle-Str. 10
13125 Berlin
Telefon: +49 (30) 941084-0
Telefax: +49 (30) 941084-112
http://www.ezag.de

Ansprechpartner:
Karolin Riehle
Öffentlichkeitsarbeit
Telefon: +49 (30) 941084-138
Fax: +49 (30) 941084-112
E-Mail: karolin.riehle@ezag.de
Für die oben stehende Pressemitteilung ist allein der jeweils angegebene Herausgeber (siehe Firmenkontakt oben) verantwortlich. Dieser ist in der Regel auch Urheber des Pressetextes, sowie der angehängten Bild-, Ton-, Video-, Medien- und Informationsmaterialien. Die United News Network GmbH übernimmt keine Haftung für die Korrektheit oder Vollständigkeit der dargestellten Meldung. Auch bei Übertragungsfehlern oder anderen Störungen haftet sie nur im Fall von Vorsatz oder grober Fahrlässigkeit. Die Nutzung von hier archivierten Informationen zur Eigeninformation und redaktionellen Weiterverarbeitung ist in der Regel kostenfrei. Bitte klären Sie vor einer Weiterverwendung urheberrechtliche Fragen mit dem angegebenen Herausgeber. Eine systematische Speicherung dieser Daten sowie die Verwendung auch von Teilen dieses Datenbankwerks sind nur mit schriftlicher Genehmigung durch die United News Network GmbH gestattet.

counterpixel